Pfizer's stock price as of January 14, 2025, is twenty-six dollars and forty-one cents, indicating a thirty-seven percent discount from its fair value of seventy-seven dollars[1]. The trading volume is thirty-two point three million shares, slightly above its average of thirty-one point two million shares[1].

Recent news includes Pfizer's invitation to the public to view and listen to a webcast of its discussion at a healthcare conference on January 6, 2025[2]. Additionally, the FDA issued its first draft guidance on the use of AI in drug and medical device development, which could impact Pfizer's future research and development efforts[2].

Major analyst updates include a consensus price target of thirty-seven dollars based on the ratings of twenty-four analysts, with the high being sixty dollars issued by Goldman Sachs on December 13, 2022, and the low being twenty-five dollars issued by Wolfe Research on November 15, 2024[3]. The three most recent analyst ratings were released by UBS, Truist Securities, and Guggenheim on January 8, 2025, December 18, 2024, and December 11, 2024, respectively, with an average price target of thirty-one dollars and thirty-three cents, suggesting a seventeen point six two percent upside[3].

Pfizer's stock forecast for 2025 and beyond is cautiously optimistic, driven by its strong product lineup and promising new treatments and vaccines[4]. However, the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors could influence stock trajectories[4]. WalletInvestor predicts a slight decline in Pfizer stock in 2025, ranging from twenty-three dollars and eighty-three cents to twenty-eight dollars and ten cents, with a level of twenty-four dollars and eighty-nine cents expected at the end of the year[4].

In terms of historical performance, Pfizer's fifty-two-week high stock price is thirty-one dollars and fifty-four cents, which is sixteen point three percent above the current share price, and its fifty-two-week low stock price is twenty-four dollars and forty-eight cents, which is nine point eight percent below the current share price[5]. The average Pfizer stock price for the last fifty-two weeks is twenty-seven dollars and eighty-three cents[5].